Market capitalization | $1.03b |
Enterprise Value | $611.32m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 58.22 |
P/S ratio (TTM) P/S ratio | 98.06 |
P/B ratio (TTM) P/B ratio | 1.95 |
Revenue growth (TTM) Revenue growth | 40.22% |
Revenue (TTM) Revenue | $10.50m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
9 Analysts have issued a Autolus Therapeutics plc forecast:
9 Analysts have issued a Autolus Therapeutics plc forecast:
Dec '23 | |
Current assets | 274 274 |
Fixed assets | 102 102 |
Total Assets | 375 375 |
Dec '23 | |
Equity | 111 111 |
Debt capital | 264 264 |
Total Capital | 375 375 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Christian Itin |
Employees | 463 |
Founded | 2014 |
Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.